Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEAL: Selinexor in Advanced Dedifferentiated Liposarcoma
NCT02606461Phase 3Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jan 2016
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of selinexor in dedifferentiated liposarcoma (DDL), sponsored by Karyopharm Therapeutics Inc.. Started Jan 2016; status: completed.
02
Drugs
selinexor
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT02606461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02606461.